Cargando…
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin
INTRODUCTION: Patients with primary or secondary immunodeficiency (PID or SID) face increased insecurity and discomfort in the light of the COVID-19 pandemic, not knowing if and to what extent their comorbidities may impact the course of a potential SARS-CoV-2 infection. Furthermore, recently availa...
Autores principales: | Volk, Andreas, Covini-Souris, Caroline, Kuehnel, Denis, De Mey, Christian, Römisch, Jürgen, Schmidt, Torben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628143/ https://www.ncbi.nlm.nih.gov/pubmed/34843105 http://dx.doi.org/10.1007/s40259-021-00511-9 |
Ejemplares similares
-
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
por: Chavda, Vivek P., et al.
Publicado: (2023) -
Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma
por: Razumikhin, Mikhail, et al.
Publicado: (2022) -
Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19
por: Nnaji, Chukwudi Arnest, et al.
Publicado: (2020) -
Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors
por: Martin, M. Carmen, et al.
Publicado: (2022) -
Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma
por: Maeda, Kenji, et al.
Publicado: (2021)